Dynamics of conditional survival and risk factors in androgen deprivation therapy for prostate cancer using a multi-institutional Japan-wide database

被引:3
作者
Chikamatsu, Sotaro [1 ]
Shiota, Masaki [1 ]
Onozawa, Mizuki [2 ]
Hinotsu, Shiro [3 ]
Kitagawa, Yasuhide [4 ]
Sakamoto, Shinichi [5 ]
Kawai, Taketo [6 ]
Eto, Masatoshi [1 ]
Kume, Haruki [6 ]
Akaza, Hideyuki [7 ]
机构
[1] Kyushu Univ, Grad Sch Med Sci, Dept Urol, Fukuoka, Japan
[2] Int Univ Hlth & Welf, Narita Hosp, Dept Urol, Chiba, Japan
[3] Sapporo Med Univ, Dept Biostat & Clin Epidemiol, Sapporo, Hokkaido, Japan
[4] Komatsu Municipal Hosp, Dept Urol, Komatsu, Japan
[5] Chiba Univ, Grad Sch Med, Dept Urol, Chiba, Japan
[6] Univ Tokyo, Grad Sch Med, Dept Urol, Tokyo, Japan
[7] Univ Tokyo, Res Ctr Adv Sci & Technol, Tokyo, Japan
关键词
androgen; anti‐ mortality; prognostic factor; prostate cancer; PROGNOSIS; INTERMITTENT;
D O I
10.1111/iju.14605
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objectives The objectives of this study were to analyze the conditional survival and prognostic factors in androgen deprivation therapy for prostate cancer using the Japan Study Group of Prostate Cancer database. Methods Data on patients treated with primary androgen deprivation therapy between 2001 and 2003 from a nationwide database of the Japan Study Group of Prostate Cancer were used. The conditional 5-year progression-free rate, cancer-specific survival and overall survival, as well as the conditional mortality owing to prostate cancer and other causes were calculated as per subgroups. Prognostic factors for progression-free rate, cancer-specific survival and overall survival at each time after androgen deprivation therapy initiation were calculated using the Cox proportional hazards model. Results The conditional 5-year progression-free rate and cancer-specific survival, but not overall survival, gradually increased with time. The prognostic impact of stage IV characteristics (T4, N1 and M1) changed over time; however, the prognostic impact of the Gleason score remained unchanged. In the subgroup analysis, prostate-specific mortality risk reduced over time in patients with stage IV prostate cancer, whereas non-prostate cancer mortality increased over time in elderly patients. Conclusions Information regarding conditional survival and mortality obtained in this study would provide a benchmark for physicians and cancer survivors.
引用
收藏
页码:927 / 935
页数:9
相关论文
共 32 条
  • [1] Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial
    Boeve, Liselotte M. S.
    Hulshof, Maarten C. C. M.
    Vis, Andre N.
    Zwinderman, Aeilko H.
    Twisk, Jos W. R.
    Witjes, Wim P. J.
    Delaere, Karl P. J.
    van Moorselaar, R. Jeroen A.
    Verhagen, Paul C. M. S.
    van Andel, George
    [J]. EUROPEAN UROLOGY, 2019, 75 (03) : 410 - 418
  • [2] Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer
    Chi, Kim N.
    Agarwal, Neeraj
    Bjartell, Anders
    Chung, Byung Ha
    Pereira de Santana Gomes, Andrea J.
    Given, Robert
    Juarez Soto, Alvaro
    Merseburger, Axel S.
    Ozguroglu, Mustafa
    Uemura, Hirotsugu
    Ye, Dingwei
    Deprince, Kris
    Naini, Vahid
    Li, Jinhui
    Cheng, Shinta
    Yu, Margaret K.
    Zhang, Ke
    Larsen, Julie S.
    McCarthy, Sharon
    Chowdhury, Simon
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (01) : 13 - 24
  • [3] Risk Assessment Among Prostate Cancer Patients Receiving Primary Androgen Deprivation Therapy
    Cooperberg, Matthew R.
    Hinotsu, Shiro
    Namiki, Mikio
    Ito, Kazuto
    Broering, Jeanette
    Carroll, Peter R.
    Akaza, Hideyuki
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (26) : 4306 - 4313
  • [4] EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer
    Cornford, Philip
    van den Bergh, Roderick C. N.
    Briers, Erik
    Van den Broeck, Thomas
    Cumberbatch, Marcus G.
    De Santis, Maria
    Fanti, Stefano
    Fossati, Nicola
    Gandaglia, Giorgio
    Gillessen, Silke
    Grivas, Nikolaos
    Grummet, Jeremy
    Henry, Ann M.
    van der Kwast, Theodorus H.
    Lam, Thomas B.
    Lardas, Michael
    Liew, Matthew
    Mason, Malcolm D.
    Moris, Lisa
    Oprea-Lager, Daniela E.
    van der Poel, Henk G.
    Rouviere, Olivier
    Schoots, Ivo G.
    Tilki, Derya
    Wiegel, Thomas
    Willemse, Peter-Paul M.
    Mottet, Nicolas
    [J]. EUROPEAN UROLOGY, 2021, 79 (02) : 263 - 282
  • [5] Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer
    Davis, Ian D.
    Martin, Andrew J.
    Stockler, Martin R.
    Begbie, Stephen
    Chi, Kim N.
    Chowdhury, Simon
    Coskinas, Xanthi
    Frydenberg, Mark
    Hague, Wendy E.
    Horvath, Lisa G.
    Joshua, Anthony M.
    Lawrence, Nicola J.
    Marx, Gavin
    McCaffrey, John
    McDermott, Ray
    McJannett, Margaret
    North, Scott A.
    Parnis, Francis
    Parulekar, Wendy
    Pook, David W.
    Reaume, M. Neil
    Sandhu, Shahneen K.
    Tan, Alvin
    Tan, T. Hsiang
    Thomson, Alastair
    Tu, Emily
    Vera-Badillo, Francisco
    Williams, Scott G.
    Yip, Sonia
    Zhang, Alison Y.
    Zielinski, Robert R.
    Sweeney, Christopher J.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (02) : 121 - 131
  • [6] Ellison Larry F, 2011, Health Rep, V22, P21
  • [7] Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
    Fizazi, Karim
    NamPhuong Tran
    Fein, Luis
    Matsubara, Nobuaki
    Rodriguez-Antolin, Alfredo
    Alekseev, Boris Y.
    Ozguroglu, Mustafa
    Ye, Dingwei
    Feyerabend, Susan
    Protheroe, Andrew
    De Porre, Peter
    Kheoh, Thian
    Park, Youn C.
    Todd, Mary B.
    Chi, Kim N.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (04) : 352 - 360
  • [8] Gleason DF., 1977, UROLOGIC PATHOLOGY P, P171
  • [9] Conditional Survival: An Assessment of the Prognosis of Patients at Time Points After Initial Diagnosis and Treatment of Locoregional Melanoma Metastasis
    Haydu, Lauren E.
    Scolyer, Richard A.
    Lo, Serigne
    Quinn, Michael J.
    Saw, Robyn P. M.
    Shannon, Kerwin F.
    Spillane, Andrew J.
    Stretch, Jonathan R.
    McCarthy, William H.
    Thompson, John F.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (15) : 1721 - +
  • [10] Conditional Survival: A Useful Concept to Provide Information on How Prognosis Evolves over Time
    Hieke, Stefanie
    Kleber, Martina
    Koenig, Christine
    Engelhardt, Monika
    Schumacher, Martin
    [J]. CLINICAL CANCER RESEARCH, 2015, 21 (07) : 1530 - 1536